Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of the American Academy of Dermatology

Topics

Medicine

Immunology

Pathology

Physiology

Dermatology

Show all topics

DOI

10.1016/j.jaad.2018.01.016

License

CC-BY-NC-ND

Other Formats

PDF